Table 2.
Summary of outcomes in the selected studies
| Study | Median follow‐up | Median duration of response | Median PFS | Median OS |
|---|---|---|---|---|
| KEYNOTE‐012 | 14.0 mo (interquartile range (IQR), 4.0‐14.0) | 12.4 mo (95% CI: 3.0‐not reached) | 2.0 mo (95% CI: 2.0‐4.0) | 13.0 mo (95% CI: 5.0‐not reached) |
| KEYNOTE‐028 | 20 mo (range, 2.2‐26.8) | 17.1 mo (range, 4.8‐22.1+) | 6.5 mo (95% CI: 3.6‐13.4) | 16.5 mo (95% CI: 10.1‐not reached) |
| KEYNOTE‐040 | 7.5 mo (IQR, 3.4‐13.3) |
Pem: 18.4 mo (95% CI: 5.8‐18.4) Sta: 5.0 mo (95% CI: 3.6‐18.8) |
3.5 mo (95% CI: 3.1‐4.4) 4.8 mo (95% CI: 4.1‐5.7) |
8.4 mo (95% CI: 6.4‐9.4) 6.9 mo (95% CI: 5.9‐8.0) |
| KEYNOTE‐055 | 9.0 mo (range, 7.0‐17.0) | 8 mo (range, 2.0‐12.0) | 2.1 mo (95% CI: 2.1‐2.1) | 8.0 mo (95% CI: 6.0‐11.0) |
| CheckMate 141 | 5.1 mo (range, 0‐16.8) |
Pem: NR Sta: NR |
2.0 mo (95% CI: 1.9‐2.1) 2.3 mo (95% CI: 1.9‐3.1) |
7.5 mo (95% CI: 5.5‐9.1) 5.1 mo (95% CI: 4.0‐6.0) |
| PCD4989g | NR | 7.4 mo (range, 2.8‐45.8) | 2.6 mo (range, 0.5‐48.4) | 6.0 mo (range, 0.5‐51.6+) |
| CONDOR | 6.0 mo (range, 0.3‐18.0) | NR | 1.9 mo (95% CI: 1.8‐2.8) | 6.0 mo (95% CI: 4.0‐11.3) |
| HAWK | 6.1 mo (range, 0.2‐24.3) | 10.3 mo | 2.1 mo (95% CI: 1.9‐3.7) | 7.1 mo (95% CI: 4.9‐9.9) |
| MedImmune | 40.3 mo (range, 1.4‐49.2) | 12.4 mo (range, 3.5‐20.5+) | 1.4 mo (95% CI: 1.4‐1.5) | 8.4 mo (95% CI: 5.7‐12.3) |
Abbreviations: 95% CI, 95% confidence interval; Niv, nivolumab group; NR, not reported; OS, overall survival; Pem, pembrolizumab group; PFS, progression‐free survival; Sta, standard‐of‐care group.